Journal article

Viral burden, inflammatory milieu and CD8( )T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study

Simone Nuessing, Edin Mifsud, Luca Hensen, Marios Koutsakos, Zhongfang Wang, Lukasz Kedzierski, Francesca Mercuri, Jean-Francois Rossignol, Aeron C Hurt, Katherine Kedzierska

Influenza and Other Respiratory Viruses | WILEY | Published : 2020


BACKGROUND: Influenza viruses cause significant morbidity and mortality, especially in young children, elderly, pregnant women and individuals with co-morbidities. Patients with severe influenza disease are typically treated with one neuraminidase inhibitor, oseltamivir or zanamivir. These antivirals need to be taken early to be most effective and often lead to the emergence of drug resistance and/or decreased drug susceptibility. Combining oseltamivir with another antiviral with an alternative mode of action has the potential to improve clinical effectiveness and reduce drug resistance. METHODS: In this study, we utilized a host-targeting molecule RM-5061, a second-generation thiazolide, in..

View full abstract